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Different schools of thought within continental philosophy claim that humans are 
instricably bound up with technology. As Ansell-Pearson states when discussing 
Bergson, Nietzsche and the transhuman condition, “technology is constitutive 
prosthetic of the human animal”,2 or the ontogenesis of the human is dependent on the 
technics and artificial instrumentation that survive well beyond the individual and are 
part and parcel of human culture. The emergence of the human represents an extended 
process of bio-technogenesis or a ‘creative evolution’ of biological and technological 
forces, where natural selection has been guided by the natural history of technics and 
technical interventions. Thus, Bergson has argued that Homo sapiens can be seen as 
Homo faber because it is a by-product of tools and technology3. Similarly, Nietzshe 
claimed that the human is a transitional figure, “something to be overcome”4. Is 
technology simply an extended phenotype, the result of our hardwired genetic impulse 
to constantly remake our world? Or is technology interwoven in nature’s design 
through what the anthropologists call ‘material culture’? While the answers to these 
questions may not be easy to grasp, recent scientific discoveries have put humans 
within striking distance of being able to re-engineer human biological destiny. 
 
At the dawn of the new millennium, while most of the world was abuzz with the Y2K 
bug potentially tripping the software codes of the emerging global information 
network, a group of biological and computer scientists powered by the latest 
supercomputers were decoding the hardware of human life.5 In a history-making 
event, when President Clinton on June 26, 2000 announced the completion of the first 
survey of the book of life, he pointed to the vast scientific landscape that has been 
opened by these discoveries:6 
Today, we are learning the language in which God created life. We 
are gaining ever more awe for the complexity, the beauty, the 
wonder of God's most divine and sacred gift. With this profound new 
knowledge, humankind is on the verge of gaining immense, new 
power to heal. Genome science will have a real impact on all our 
lives - and even more, on the lives of our children. It will 
revolutionize the diagnosis, prevention and treatment of most, if not 
all, human diseases. In coming years, doctors increasingly will be 
able to cure diseases like Alzheimer's, Parkinson's, diabetes and 
cancer by attacking their genetic roots. Just to offer one example, 
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patients with some forms of leukemia and breast cancer already are 
being treated in clinical trials with sophisticated new drugs that 
precisely target the faulty genes and cancer cells, with little or no 
risk to healthy cells. In fact, it is now conceivable that our children's 
children will know the term cancer only as a constellation of stars. 
As new genetic pathways are discovered for different human diseases, such as breast 
cancer, prostate cancer, coronary artery disease, myocardial infarction, obesity and 
diabetes, the coupling of bioinformatics and genomics is elevating biotechnology to 
newer heights.7 Not unlike physics and chemistry that drove the economic 
development of the industrialized West, today biology as a ‘big science’ seems poised 
to transform the information economy.8 According to an Ernst & Young report, as the 
biotechnology sector accumulates 30 years of experience (dating back to the 
Genentech IPO in 19769), it is generating over US$60 billion in revenue, booming 
across the globe (including developing economies in Asia-Pacific), and creating 
hundreds of human therapies and diagnostic products.10 This essay reviews three 
recent books that provide a closer look at the coming of the biotech century11 or what 
has been called the biotech age.12 
 
Several important themes emerge from this collection of books: First, as the 
biotechnology and bioinformatics industries mature, with the potential to 
fundamentally reshape modern medicine, the clash between science and spirituality is 
simply unavoidable. Second, the new biotechnology products fueled by genomics will 
completely reshape our understanding of human development with their power to 
mine the human genome. Finally, the rise of biotechnology as a ‘big science’ is 
underwritten by speculative market capital, termed “biocapital”, partly funded by big 
pharma and venture capital firms. Biocapital is extending its reach in the form of 
global human trials to low-income economies, raising the spectre of neocolonialism. 
Here, I briefly discuss the implications of the biotech revolution for the behavioural 
and social sciences by focusing on the human-technology nexus, which is 
transforming human nature as described by the process of human technogenesis or 
through the co-evolution of humans and technology.13 These developments also raise 
unique challenges for posthuman law as an instrument of social and economic 
policy.14 
 
Stealing Genes from the Gods 
Lee Silver presents a sweeping view of the social policy implications of 
biotechnology within the highly charged context of science and spirituality. In the 
ambitious book, Challenging Nature,15 he drives home the point that humans do not 
have a privileged position within “the great chain of being” or scala naturæ, and that 
the human biological evolution as described by many Darwinians has essentially 
come to a gradual halt as we no longer live in small isolates and are not confronted 
with daily pressures of survival.16 On the other hand, humans are in the position to 
play dice with the Gods by designing possible human futures through human 
technological innovation.17 He cautions that a well-reasoned decision supporting 
biotechnology can only advance humanity, health, and the environment, setting aside 
any leftist ‘new-age’ ideas or right-wing conservative ideologies. Depending on your 
viewpoint, readers may view Silver as possessing Promethean creativity, trying to 
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‘steal genes’ from the Gods, or striking a Faustian bargain in advancing human 
knowledge.  
 
Silver presents a broad survey of the field of biotechnology and how it is pushing up 
against some of the highly cherished views about human development. His 
dispassionate view of a scientist, who sequences genes on a daily basis, covers a 
broad span of human history tracking the vicissitudes of the gene from ancient 
biotechnology (including food preservation and animal breeding) to the Human 
Genome Project. We have always taken up the challenge to tinker with human nature 
as agriculturalists and industrialists, using new techniques to harness the power of 
nature. Genomics is the latest scientific leap we have made, except it touches on the 
very core of what it means to be human. In the final analysis, according to Silver, we 
must fully embrace the challenge of genomics and lead humanity to the next level of 
human development, devoid of disease or illness, poverty or famines, and a 
sustainable biosphere.  
 
Silver has traveled the globe interviewing lay people about the ‘ways of knowing’ of 
many spiritual traditions. While acknowledging the persistent utility of spirituality in 
the minds of everyday folks, he predicts that for the foreseeable future both science 
and spirituality will continue to be intertwined as counterpoints of human destiny. He 
offers an insightful understanding of the resistance to biotechnology as stemming 
from a central belief that tinkering with human nature calls into question histoire 
d’origine or the origin stories of many traditional belief systems. Charles Darwin, as a 
Christian, was well aware of this and had delayed the publication of The Origin of 
Species18 by almost 20 years. Almost 150 years later, the difference between the 
Darwinian views of biological evolution as gradual, halting and non-purposive versus 
religious belief that life is characteristically miraculous and sudden, continues to 
trouble our conscience collective or the human mind. 
 
Christian fundamentalists (whether Protestant or Catholic) generally believe that 
human beings receive a soul from God at conception. They shun embryonic stem cell 
research as a form of killing of human life, but are sympathethic towards agricultural 
biotechnology. Likewise, there is a growing number of post-Christian Europeans and 
Americans who have adopted a kind of nature-religion. They espouse a fuzzy belief in 
God that is empowered by Mother Nature as ‘Goddess’, a kind of Gaia principle 
animating the biosphere. Genetically engineered plant genes are seen as an attack on 
the sovereignty of the Goddess. While on the surface, fundamentalists and post-
Christian organic food devotees may not have much in common, however, both are 
deeply rooted in the monotheistic belief against ‘playing God’, prevalent in the 
Western developed societies.  
 
In many Eastern cultures, ‘playing God’ does not carry this negative connotation, 
where spirit or atman is eternal and self-evolving. These cultures have a view of 
spirituality that is continuous with human evolution, thus the idea of tinkering with 
God’s natural design may not be anathema.19 While there have been recent political 
stalemates within the stem cell debate in the US, according to Silver, Asian scientists 
are less likely to be held back by the regulatory pressures that may impede science 
and policy.20 
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Looking at the variation in spiritual forms and practices in different societies, Silver 
claims that spirituality itself is adaptive and may have a strong genetic underpinning, 
as documented by the DRD4 gene. He cites evidence that locates the emergence of 
DRD4 mutation to 30,000 to 50,000 years ago, which then rapidly spread through 
human populations, coinciding with the archeological evidence of the emergence of 
the belief in an afterlife and salvation. Silver concludes that the biological evidence 
coupled with cultural analyses, suggests that the existence of spirituality is 
biologically determined and does not necessitate divine intervention or intelligent 
design for its persistence throughout the ages. One of the latest challenges for 
genomics is to determine the genetic basis for the emergence of the human mind, 
including the ability to use tools, symbols and language.21 
 
Silver does confront the contentious issue of ‘embryonic souls’, or when germinal life 
acquires a soul. Before the advent of the microscope the beginning of cellular life was 
a mystery. From Aristotle to Aquinas the idea of a soul has a long history in Western 
culture. Where should we draw the line between the life and death of an embryonic 
soul? The recent case of Rosa Acuna in the Appellate Court of New Jersey and other 
cases like it around the country underscore the highly politicized environment. Rosa 
Acuna is a Catholic woman, who received an abortion at 5 weeks of pregnancy and 
then claimed that her physician, Dr. Sheldon Turkish, did not inform her that life 
begins at conception. In response to a question from the patient, “My baby was 
already there?” the physician said something like, “Don’t be stupid, it is just some 
blood”.22 According to Silver, who consulted on the case on behalf of Dr. Turkish, the 
idea of embryonic souls is a matter of religious belief, where words like ‘dignity’, 
‘sanctity’ and ‘life’ are often equated with the ‘natural law’, while tampering with the 
biological processes of human reproduction is considered simply unnatural. The 
theory of intelligent design is the latest instance of a pro-life view guised as academic 
science that holds up a Christian doctrine.  
 
Similarly, the recent politicization of stem cell research reflects how those who 
believe in the ‘culture of life’ have locked horns again with those who believe in a 
progressive scientific view. Until 1998 most scientists had no reason to use human 
embryos in their laboratories. Federal government provided no money for it and most 
of it was handled by IVF clinics and private funding. The cloning of Dolly, using a 
technique to create copies of the original DNA later implanted into another sheep’s 
nucleus, brought to the forefront the whole issue of stem cell research. Genes are 
essentially digital files encoded within the DNA molecules that can be copied and 
recopied. Regenerative embryonic stem cells can help alleviate many of the hard-to-
treat ailments through the process of neurogenesis.23 Spurred by this new discovery, 
within five years of the cloning of Dolly, today many scientists believe that research 
on embryonic stem cells offers the greatest promise for the treatment of many 
diseases. We are at a critical moment in the development of this technology that can 
be advanced in a better political climate, unlocking treatments for many of the genetic 
ailments, especially, neurological or developmental disorders. 
 
Finally, in traveling the globe, Silver takes the reader on a journey through the 
Amazon rainforest. He is in search of the natural wonder and harmony of Mother 
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Nature or ‘the paradise lost’. Instead, what he observes is a jungle full of teeming 
organisms, animals and plants, competing with each other for limited resources in 
order to survive; Silver states that the Amazon is like the capitalist market economy 
with intense competition among the same species to outperform each other. Eternal 
harmony may be difficult to locate in the Amazon, where one wrong move can easily 
turn you into a prey or the hunted. In other words, the harmony that most ‘New Age’ 
religions endow with nature is simply a matter of faith and not an observed fact. 
When left to its own devices, Mother Nature without human intervention and industry 
would not know how to direct its course. Natural change is random, non-directional 
and non-purposive. Based on Silver’s observations, the readers may feel a sobering or 
almost depressing view of life is dawning upon them. As a counterpoint, Silver seems 
determined to highlight the benefits of biotechnology with the appropriate safeguards 
for humanity. Silver’s scientific outlook is respectful of traditional belief systems, 
while advancing a deeper understanding of genomics, which makes this book 
essential reading for those who are either for or against biotechnology. For a 
somewhat different perspective, we must assess how the biotech revolution is 
changing the culture and politics of science itself. 
 
Genomic Data Become Flesh 
In a timely and insightful book from the ‘science, technology and society’ 
perspective,24 Eugene Thacker explains how data have become flesh, how the 
genomic technologies, the sequencing machines, and the bits of DNA code on 
computer chips are transforming the very fabric of life. The Global Genome25 
elaborates in great detail on the emerging dialectic between biology and technology. 
Genomic information has become synonymous with the hardware and software 
involved in the computational process of sequencing and decoding of the human 
genome. Given the confluence of the university networks, industry and government, 
the recently coded genomic information is increasingly available online as DNA chips 
and genetic databases for various disease populations; hence, the genome by 
definition is a global phenomenon. 
 
However, the age-old tension between biology and technology has now been elevated 
to the level of political economy as the biotech industry is showing signs of becoming 
a ‘big science’ not unlike nuclear physics in its heyday. As an industry that claims to 
be working on natural matter with high-speed computer chips, it has obliterated the 
distinction between the natural and the artificial, especially as we acknowledge that 
any uniquely identified genetic code or pathway can be patented as a separate entity if 
it is artificially reproduced in the laboratory. In essence, the very substance of life 
itself has become part and parcel of the production, distribution and consumption 
cycle within emergent forms of global capitalism. 
 
Thacker’s work becomes even more interesting and challenging when he examines 
the old debates within population genetics around ‘race’. While the new population 
genomics movement is not interested in the issue of ‘race’, which is essentially a 
political category rather than a biological one, ‘race’ nonetheless is intertwined in the 
attempt to build databases on diverse populations around the world.26 Thacker raises 
the spectre of bio-colonialism using Fanon’s example of the colonial doctor who 
practices medicine in the service of the imperial powers27.  
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Thacker attempts to rewrite the logic of the production economy for the biotech age. 
He demonstrates how the very terms used to define classical capitalism are now in 
need of revision as we are moving towards a biomaterial economy, where life itself 
represents a biomaterial product (e.g., assay kits, DNA sequencers, genetic databases). 
Similarly, the threats to our security are increasingly from bio-warfare and bio-
terrorism, as the government reminds us regularly. 
 
Thacker examines the science of regenerative medicine in great detail. This represents 
the cutting edge of tissue engineering and a multidisciplinary approach to life 
sciences. Once a medical approach for repairing failed organs, tissue engineering in 
the biotech age promises to harness the body’s regenerative capacity to recreate 
perpetual life within living organisms. By genetically manipulating the processes of 
human growth in vivo, scientists have a vision of the human body that will eventually 
transcend its materiality, its malfunctions and diseases and of course the biological 
clock. Indeed, the new biology offers nothing less than material salvation and aspires 
to be truly the biology of liberation or liberation biology,28 the new religion of the 
biotech age.29 
 
The key strength of Thacker’s book is its emphasis on the bioinformatics revolution: 
how the coupling of genomics and informatics will transform life science and its 
cultural and artistic representations. The author is trained in comparative literature and 
communication sciences, disciplines steeped in Post-Modern theory, cultural studies 
and literary criticism; he draws on these sources of knowledge to provide vivid 
examples of the new media constructions of bio-materiality, bio-media and bio-art. 
While the book is focused on the globalization of the genome, it does not reach out to 
low-income economies to understand the impact of biotechnology on diverse 
populations; for this we must turn to an anthropological account of the 
commercialization of biotechnology. 
 
Commercialising the Code of Life 
Kaushik Sunder Rajan’s book, Biocapital: 30 makes a rare contribution to the analysis 
of globalization and commercialization of biotechnology in developed and developing 
economies. Backed by big-pharma and the buoyant optimism of the market, 
biotechnology is spreading to far flung places around the world, searching for better 
business processes, human subjects, clinical expertise, and of course new markets. 
This raises some fundamental concerns about informed consent and international 
protocols on clinical research, based on previous case law31 and supported by the 
author’s study of Neo-Marxist and Foucauldian theories. 
 
The main strength of the book, the culmination of a doctoral thesis completed at MIT, 
is the multi-site ethnography that took five years to complete (1999-2004). What the 
author calls the “upstream and downstream of drug development” is very much 
influenced by emerging biotechnological products. While big pharma and biotech 
have very different histories and business models, they meet somewhere near the 
halfway point of the drug development process. Biotech companies work upstream, 
trying to move molecules to production past phase 1 and 2 clinical trials to the point 
where they become potentially interesting targets for a big pharma. Big pharma, with 
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its proven track record of taking drugs to profitability, acts as the gatekeeper and 
lender of capital to foster molecules to maturity. Sunder provides detailed examples of 
this intricate dynamic as it is played out in the drug development marketplace. 
 
The emergence of generic manufacturers (eg, Teva, Dr. Reddy, Ranbaxy and others) 
in the developing parts of the world is yet another element that makes the flow of 
biocapital truly global. Developing economies have different patent rights, which 
allow manufactures to reverse engineer branded products as generic drugs, driving 
prices downwards and fostering greater competition with branded drugs. This has 
fueled a highly competitive legal environment for the branded manufacturers, a 
majority of which are based in the developed economies of the US, EU and Japan.  
 
As a window on the emerging forms of global bio-capitalism, the author gives a 
glimpse of the shifting perspectives within the US and Indian biotech industries. 
Sunder claims that while the US drug industry has shifted towards a ‘gifting 
economy’ with inducements for setting up freely accessible databases, economies in 
the developing world, especially India, are geared towards globalization, aspiring to 
be business processing shops for the US drug industry. In a kind of economic 
nationalism, the Indian government promotes the genetic richness of the Indian 
population as an asset for the American and European drug industry.  
 
The flow and speed of genomic information is truly mind-numbing, a mark of a shift 
in production, distribution and consumption. Both big pharma and biotech rely on the 
flow and speed of the information exchange to be ultimately successful in promoting 
their products. In the increasingly transnational flow of information, bioethics may get 
short shrift, especially when local views on the exchange of sample and biological 
materials are not extracted. Sunder makes the important claim that the industry lacks a 
truly transnational view on the bioethical dilemmas that confront genomics.  
  
Sunder provides many other interesting observations that are corroborated by a recent 
report on the state of the biotech sector in India.32 Conducted by the Center for Global 
Health at the University of Toronto, the report claims that while India is providing 
back-office services to many of the major biotech companies and manufacturing 
several novel biopharma drugs and vaccines, it has not become a major hub for 
biotech innovation. India has arrived and is poised to make a global contribution, yet 
faces many local health challenges. Indian biotech is concentrated on at least four 
types of products and services: low-priced vaccines, non-vaccine drugs and therapies, 
new product development, and outsourcing or contract services. Harmonisation of the 
regulatory system, biotech training of personnel, and a focus on the public health of 
the Indian population would further the Indian biotech industry. Given the limited 
healthcare spending by the government, these initiatives may be advanced by the in-
flow of multinational capital or biocapital. In an emerging global economy, this would 
benefit the Indian population while advancing biotech industry and policy in 
developed economies. 
 
Technogenesis Redesigns Phylogenesis 
Reviewing these books makes it clear that there is a paradigm-shift underway within 
the human-technology nexus. The interaction between humans and technology has 
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reached an unprecedented dimension, where bioinformatics, robotics and life 
extension technologies with ever deeper reach into everyday human experience will 
structurally modify what it means to be human. In an earlier publication, I have 
outlined the evolutionary dialectic of humans and technology within the context of 
behavioural sciences - termed “human technogenesis” - which gives rise to new 
interactive technologies and to new forms and structures of the human mind.33 
 
In the post-genomic world, where technology may reshape the very fabric of human 
life, human-led technogenesis is poised to reproduce in vitro and in vivo phylogenetic 
evolution. Indeed, the biological sciences may give new meaning to Ernst Haeckel’s 
debunked recapitulation theory,34 the idea that ontogeny recapitulates phylogeny can 
now be represented as technogenesis redesigns phylogenesis. The decoding of the 
human genome allows the history of our species or phylogenetic evolution to be 
redesigned with the help of the post-genomic technologies.35 In other words, human-
led technogenesis is at the precipice of reengineering human life in the laboratory 
with advanced reproductive technologies, such as IVF, cloning and stem cells. While 
archaeology and anthropology have been witness to the interaction between humans 
and technology dating back to pre-historic times, we are approaching a tipping point 
in this evolutionary dialectic where the decoding of ‘the book of life’ empowers 
humans to redesign human development. This shift may not be neat and may be 
highly contested by many secularists and spiritualists alike. However, technofuturists 
are claiming that “the singularity is near,” where humans empowered with the new 
technology will transcend biology.36 
 
The levels of interaction between technology and human development capture the 
processes whereby human-led technogenesis redesigns phylogenesis. First, we are 
intensifying our reliance on newer forms of information and communication 
technologies such as PC’s, cell phones, PDAs and wireless beepers to regulate our 
behaviour. These interactive tools are reshaping our everyday cultural environment in 
a significant manner. Second, we are using wearable virtual devices around the ear, 
eyes, waist, wrist and neck that form a seamless relationship with human body and its 
daily functions and bio-rhythms. Wearable devices may include monitoring devices 
we use in a hospital or under clinical observation as well as performance enhancers 
used in normal functioning, such as wrist-watches, hand-free wireless devices and 
other types of jewelry.  
 
Next, technology enters the human body and is responsible for regulating deep-rooted 
biological mechanisms that are inherited and phylogenetic in origin. Medical devices 
such as pacemakers that are used in chronic conditions to monitor and regulate the 
human behaviour have been in widespread use. Recently approved and experimental 
treatments for movement disorders, Parkinson’s disease, depression and other 
neurological disorders rely on neuroimplants. For example, the procedure called Deep 
Brain Stimulation includes monitoring brain activity via computer devices both 
inserted and external to the human body, where neuroimplants stimulate parts of the 
brain to correct for synaptic transmissions .37 Neurotechnology may go even a step 
further in treating neurodevelopmental disorders, such as Parkinson’s disease,38 where 
the creation of new germinal cells and the pruning of degenerative cells is facilitated 
by the process called neurogenesis. Using these recent advances in stem cell research, 
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technology may completely modulate biology, while the impact of cultural 
environment may seem remote. 
 
Neuroscientists have also suggested that humans may be implanted with neurochips to 
achieve higher cognitive potential; neurotechnology companies in collaboration with 
pharmaceutical companies plan to achieve this goal.39 Humanists amongst us may be 
repulsed by these ideas, yet every society may develop its own adaptive cultural 
pathway to either adopt or reject these technological developments, just as societies 
have previously done with the onslaught of industrialization and the information 
economy.  
 
Liberation Biology Meets Our Posthuman Future 
Studying bioethics at a Jesuit university gave me a sense of moral urgency about 
medical ethics that touch on human nature, life and death, and God and man. The 
ethical debates were not mere abstractions; they were about something very serious 
and impending. Ultimately, they were about our deep humanity and our presumption 
or the ability to step into God’s shoes. Perhaps my upbringing as a Hindu made me 
sensitive to these debates. Working in the pharmaceutical and biotech sector has 
returned me to these questions, except now the urgency is even greater as science has 
advanced much farther. The evidence seems highly suggestive that as technology 
appropriates and transforms the natural process of human development, it begins to 
define a posthuman world.40 The birth of the posthuman is biologically driven by the 
contemporary conditions of human existence, which do not foster natural human 
evolution or natural selection of traits. In other words, non-biological change or the 
coevolution of humans and technology, of which the biotechnology sector is an ideal 
example, are driven by different forms of human technogenesis at the institutional 
level. It is the co-evolution of humans and technology that may lead to the emergence 
and selection of human traits in the long run. This review has presented a 
multidisciplinary view of human technogenesis as seen through the genomics 
revolution, including perspectives from molecular biology, new media, anthropology 
and social policy.  
 
Indeed, Francis Fukuyama in Our Posthuman Future41 claims that the double vision 
of Orwell and Huxley are fully dawning upon us; the surveillance society created by 
the information technology revolution has given new meaning to ‘Big Brother’, while 
the new forms of reproductive technologies are steadily ushering in the ‘Brave New 
World’. In light of these developments some legal scholars have called for a 
posthuman law which applies to information and communication technologies, 
including technologies at the interface of bioinformatics.  
 
Within the legal framework, Sandra Braman has articulated the condition of 
posthumanism as it pertains to information technologies: 
 
It has been an unspoken assumption that the law is made by humans 
for humans. That assumption no longer holds: The subject of 
information policy is [sic] increasingly flows between machines, 
machinic rather than social values play ever-more important roles in 
decision-making, and information policy for human society is being 
supplemented, supplanted, and superceded by machinic decision-
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making. As the barrier between the human and machinic falls with 
implantation of chips within the body and other types of intimate 
relationships, and as dependence upon the information 
infrastructure continues to grow, the question of the rights of 
technological systems themselves is entering the legal system[...]All 
of these are manifestations of a transformation in the legal system so 
fundamental that it may be said that we are entering a period of 
posthuman law. 42 
 
As the genomic gold rush picks up pace, the tensions between human law and 
posthuman culture is likely to escalate. Judging by a recent review, the race to 
uncover the genetic basis of each human disease with large cohorts of cases and 
controls is underway.43 There is a rush to patent the information and commercialize 
even the smallest of genomic nuggets. While approximately 20% of the human 
genome has been patented, this number is likely to increase rapidly. This makes the 
ultimate step of linking genes with a disease and in turn with a particular therapy that 
much more difficult. For instance, the development of a panel of gene markers for a 
disease might take negotiations with multiple and diverse interests who may own 
different components of the patent for that disease. As it has been aptly stated, “Who 
then owns the genome?”44 How can we allow for an open exchange of information 
that advances science and policy for the common good? These are some of the 
challenges confronting us as liberation biology, the new religion, reconstitutes life in 
the posthuman world. 
 
Patenting Life 2.0 
The science fiction writer Michael Crichton has argued that an underfinanced and 
understaffed US patent office (USPTO) misinterpreted the Supreme Court precedence 
when it allowed genes to be patented.45 “Genes aren’t human inventions; they are 
features of the natural world,” he wrote in a New York Times article. Jeremy Rifkin 
and many other activists would claim that patenting genes has blocked innovation and 
patient care.46 Genomic discoveries are a global public health good, part and parcel of 
our common heritage.47 On the other hand, a new generation of scientists called 
Synthetic Biologists, are creating synthetic organisms, challenging nature’s monopoly 
on the plethora of living organisms. They want to patent everything under the sun and 
rewrite the code of life dubbed ‘Life 2.0’.48 The task of the USPTO has become 
increasingly complex in the post-genomic world.  
 
Life science and biotechnology is an expensive enterprise and relies on strong patent 
protection for innovation. However, a string of recent decisions have made it tougher 
for life science patents to be acquired and defended. In the eBay, Inc. v. 
MercExchange, L.L.C. (May, 2006), the US Supreme Court reduced permanent 
injunctions for infringements of a patent, weakening the value of patent rights.49 In 
MedImmune, Inc. v. Genentech, Inc. (Jan, 2007), the court made it easier for a patent 
to be challenged by a licensee.50 Most recently in KSR International, Inc. v. Teleflex, 
Inc., the US courts lowered the obviousness standard for a patent, making it easier to 
invalidate a patent.51 
 
These recent decisions also reflect the overall tone of the Patent Reform Act of 2007, 
which has been heavily driven by the software development industry.52 Obvious 
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limitations for biotechnology patents consist of longer incubation periods and longer 
claims of exclusivity. Unlike the software products, biotech products exist in a highly 
regulated environment, with much greater risks of liability. Thus, it is currently 
believed by many legal experts that the forthcoming changes from the USPTO can be 
damaging for the life sciences, especially, when the limitations to the continuation 
claims are considered which makes it difficult to obtain full coverage of a 
biotechnology invention.53 
 
The technical discussions about patents have real-life implications for human 
development. Human development as defined by many developmental agencies 
reflects the progressive aim of improving the lives and health conditions of people 
around the world. While the laws dealing with the post-genomics revolution are in 
flux in the US, there is little attention paid to these issues in developing countries. 
However, in a globalized world where outsourcing of biotechnology products is fast 
becoming the norm, ignoring the emerging economies in the developing world is a 
luxury we can not afford. The burden of disease from life-long, genetic disorders can 
be gradually lifted if the legal environment is conducive to innovation in diagnostics, 
drug development and delivery of healthcare. As the biotechnology discoveries begin 
to accumulate, we are facing an uphill climb, with many regulatory, financial, and 
business challenges towards creating open access to genomics “public health goods”54 
for populations around the world. 
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